CAR-T Wannabe? Immuno-oncology Start-up snowballs $102M for Series A Fund

21/10/2015 - 3 minutes

Gritstone Pharmaceuticals is a US start-up which will focus on R&D of its new CAR-T cancer therapy technique: tumor-specific neo-antigen (TSNA). An impressive financial syndicate is backing its launch this month, having achieved a £102M series A pot for their lung cancer research.

This cash is a clear indication that this start-up has the 3 major components to a successful Biotech under its belt; a novel-platform, tenure + biotech expertise from the field (i.e. as it is led by a co-founder of the US biotech Clovis) and research excellence from King’s College London (UK) and Institute Gustave-Roussy (France).

Tumor-specific neo-antigen (TSNA) field is a personalized immuno-oncology technique akin to CAR-T (which you can read about in our Oncology overview here). This is a type of checkpoint inhibition therapy which works in almost the exact same way as CAR-T, but instead it targets tumoric antigens which are unique to cancerous cells (considered entirely foreign to the body’s immune system).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!